Flores Carlos, Rohn Jennifer L
Biozentrum, University of Basel, Basel, Switzerland.
Centre for Urological Biology, Division of Medicine, University College London, London, UK.
Nat Microbiol. 2025 Mar;10(3):627-645. doi: 10.1038/s41564-025-01926-8. Epub 2025 Feb 10.
Urinary tract infections (UTIs) are compounded by antimicrobial resistance, which increases the risk of UTI recurrence and antibiotic treatment failure. This also intensifies the burden of disease upon healthcare systems worldwide, and of morbidity and mortality. Uropathogen adhesion is a critical step in the pathogenic process, as has been mainly shown for Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Streptococcus agalactiae, Proteus, Enterococcus and Staphylococcus species. Although many bacterial adhesion molecules from these uropathogens have been described, our understanding of their contributions to UTIs is limited. Here we explore knowledge gaps in the UTI field, as we discuss the broader repertoire of uropathogen adhesins, including their role beyond initial attachment and the counter-responses of the host immune system. Finally, we describe the development of therapeutic approaches that target uropathogenic adhesion strategies and provide potential alternatives to antibiotics.
尿路感染(UTIs)因抗菌药物耐药性而愈发复杂,这增加了UTI复发和抗生素治疗失败的风险。这也加重了全球医疗系统的疾病负担,以及发病率和死亡率。尿路病原体黏附是致病过程中的关键步骤,主要在大肠杆菌、铜绿假单胞菌、肺炎克雷伯菌、无乳链球菌、变形杆菌、肠球菌和葡萄球菌属中得到证实。尽管已经描述了这些尿路病原体的许多细菌黏附分子,但我们对它们在UTIs中的作用了解有限。在这里,我们探讨了UTI领域的知识空白,讨论了尿路病原体黏附素的更广泛种类,包括它们在初始附着之外的作用以及宿主免疫系统的应对反应。最后,我们描述了针对尿路致病性黏附策略的治疗方法的发展,并提供了抗生素的潜在替代品。